Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes

@inproceedings{MacDonald2016AfliberceptEV,
  title={Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes},
  author={Douglas A. MacDonald and Joel H. Martin and Kathir K. Muthusamy and Jiann-Kae Luo and Erica A. Pyles and Ashique Rafique and Tammy T. Huang and Terra B. Potocky and Yang Liu and Jingtai Cao and Françoise Bono and Nathalie Delesque and Pierre Savi and John L. Francis and Ali Amirkhosravi and Todd Meyer and Carmelo Romano and Meredith Glinka and George D. Yancopoulos and Neil Stahl and Stanley J. Wiegand and Nicholas J. Papadopoulos},
  booktitle={Angiogenesis},
  year={2016}
}
Anti-vascular endothelial growth factor (VEGF) therapies have improved clinical outcomes for patients with cancers and retinal vascular diseases. Three anti-VEGF agents, pegaptanib, ranibizumab, and aflibercept, are approved for ophthalmic indications, while bevacizumab is approved to treat colorectal, lung, and renal cancers, but is also used off-label to treat ocular vascular diseases. The efficacy of bevacizumab relative to ranibizumab in treating neovascular age-related macular degeneration… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS